Literature DB >> 19841074

The presence of CD14 overcomes evasion of innate immune responses by virulent Francisella tularensis in human dendritic cells in vitro and pulmonary cells in vivo.

Jennifer C Chase1, Catharine M Bosio.   

Abstract

Francisella tularensis is a Gram-negative bacterium that causes acute, lethal disease following inhalation. We have previously shown that viable F. tularensis fails to stimulate secretion of proinflammatory cytokines following infection of human dendritic cells (hDC) in vitro and pulmonary cells in vivo. Here we demonstrate that the presence of the CD14 receptor is critical for detection of virulent F. tularensis strain SchuS4 by dendritic cells, monocytes, and pulmonary cells. Addition of soluble CD14 (sCD14) to hDC restored cytokine production following infection with strain SchuS4. In contrast, addition of anti-CD14 to monocyte cultures inhibited the ability of these cells to respond to strain SchuS4. Addition of CD14 or blocking CD14 following SchuS4 infection in dendritic cells and monocytes, respectively, was not due to alterations in phagocytosis or replication of the bacterium in these cells. Administration of sCD14 in vivo also restored cytokine production following infection with strain SchuS4, as assessed by increased concentrations of tumor necrosis factor alpha (TNF-alpha), interleukin-1beta (IL-1beta), IL-12p70, and IL-6 in the lungs of mice receiving sCD14 compared to mock-treated controls. In contrast to homogenous cultures of monocytes or dendritic cells infected in vitro, mice treated with sCD14 in vivo also exhibited controlled bacterial replication and dissemination compared to mock-treated controls. Interestingly, animals that lacked CD14 were not more susceptible or resistant to pulmonary infection with SchuS4. Together, these data support the hypothesis that the absence or low abundance of CD14 on hDC and in the lung contributes to evasion of innate immunity by virulent F. tularensis. However, CD14 is not required for development of inflammation during the last 24 to 48 h of SchuS4 infection. Thus, the presence of this receptor may aid in control of virulent F. tularensis infections at early, but not late, stages of infection.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19841074      PMCID: PMC2798182          DOI: 10.1128/IAI.00750-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  65 in total

1.  Characterization of Francisella tularensis outer membrane proteins.

Authors:  Jason F Huntley; Patrick G Conley; Kayla E Hagman; Michael V Norgard
Journal:  J Bacteriol       Date:  2006-11-17       Impact factor: 3.490

2.  Active suppression of the pulmonary immune response by Francisella tularensis Schu4.

Authors:  Catharine M Bosio; Helle Bielefeldt-Ohmann; John T Belisle
Journal:  J Immunol       Date:  2007-04-01       Impact factor: 5.422

3.  Autophagy-mediated reentry of Francisella tularensis into the endocytic compartment after cytoplasmic replication.

Authors:  Claire Checroun; Tara D Wehrly; Elizabeth R Fischer; Stanley F Hayes; Jean Celli
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-18       Impact factor: 11.205

4.  Francisella tularensis replicates within alveolar type II epithelial cells in vitro and in vivo following inhalation.

Authors:  Joshua D Hall; Robin R Craven; James R Fuller; Raymond J Pickles; Thomas H Kawula
Journal:  Infect Immun       Date:  2006-11-06       Impact factor: 3.441

Review 5.  Tularaemia.

Authors:  A Tärnvik; L Berglund
Journal:  Eur Respir J       Date:  2003-02       Impact factor: 16.671

6.  Experimental tularemia in mice challenged by aerosol or intradermally with virulent strains of Francisella tularensis: bacteriologic and histopathologic studies.

Authors:  J Wayne Conlan; Wangxue Chen; Hua Shen; Ann Webb; Rhonda KuoLee
Journal:  Microb Pathog       Date:  2003-05       Impact factor: 3.738

7.  Toll-like receptor 2-mediated signaling requirements for Francisella tularensis live vaccine strain infection of murine macrophages.

Authors:  Leah E Cole; Kari Ann Shirey; Eileen Barry; Araceli Santiago; Prasad Rallabhandi; Karen L Elkins; Adam C Puche; Suzanne M Michalek; Stefanie N Vogel
Journal:  Infect Immun       Date:  2007-05-21       Impact factor: 3.441

8.  Francisella tularensis has a significant extracellular phase in infected mice.

Authors:  Colin A Forestal; Meenakshi Malik; Sally V Catlett; Anne G Savitt; Jorge L Benach; Timothy J Sellati; Martha B Furie
Journal:  J Infect Dis       Date:  2007-05-23       Impact factor: 5.226

Review 9.  Interleukin-12 and the regulation of innate resistance and adaptive immunity.

Authors:  Giorgio Trinchieri
Journal:  Nat Rev Immunol       Date:  2003-02       Impact factor: 53.106

10.  Brucella suis prevents human dendritic cell maturation and antigen presentation through regulation of tumor necrosis factor alpha secretion.

Authors:  Elisabeth Billard; Jacques Dornand; Antoine Gross
Journal:  Infect Immun       Date:  2007-07-16       Impact factor: 3.441

View more
  21 in total

1.  Proteomic analysis of bronchoalveolar lavage fluid proteins from mice infected with Francisella tularensis ssp. novicida.

Authors:  Susan M Varnum; Bobbie-Jo M Webb-Robertson; Joel G Pounds; Ronald J Moore; Richard D Smith; Charles W Frevert; Shawn J Skerrett; David Wunschel
Journal:  J Proteome Res       Date:  2012-06-22       Impact factor: 4.466

2.  IFN-β mediates suppression of IL-12p40 in human dendritic cells following infection with virulent Francisella tularensis.

Authors:  Timothy J Bauler; Jennifer C Chase; Catharine M Bosio
Journal:  J Immunol       Date:  2011-07-13       Impact factor: 5.422

3.  Cd14 SNPs regulate the innate immune response.

Authors:  Hong-Hsing Liu; Yajing Hu; Ming Zheng; Megan M Suhoski; Edgar G Engleman; David L Dill; Matt Hudnall; Jianmei Wang; Rosanne Spolski; Warren J Leonard; Gary Peltz
Journal:  Mol Immunol       Date:  2012-03-23       Impact factor: 4.407

4.  Long lived protection against pneumonic tularemia is correlated with cellular immunity in peripheral, not pulmonary, organs.

Authors:  Rebecca V Anderson; Deborah D Crane; Catharine M Bosio
Journal:  Vaccine       Date:  2010-08-03       Impact factor: 3.641

5.  Temporal Requirement for Pulmonary Resident and Circulating T Cells during Virulent Francisella tularensis Infection.

Authors:  Lydia M Roberts; Tara D Wehrly; Robin M Ireland; Deborah D Crane; Dana P Scott; Catharine M Bosio
Journal:  J Immunol       Date:  2018-07-06       Impact factor: 5.422

6.  Francisella infection triggers activation of the AIM2 inflammasome in murine dendritic cells.

Authors:  Kamila Belhocine; Denise M Monack
Journal:  Cell Microbiol       Date:  2011-10-17       Impact factor: 3.715

7.  Effective, broad spectrum control of virulent bacterial infections using cationic DNA liposome complexes combined with bacterial antigens.

Authors:  Robin Ireland; Norma Olivares-Zavaleta; Jonathan M Warawa; Frank C Gherardini; Clayton Jarrett; B Joseph Hinnebusch; John T Belisle; Jeffery Fairman; Catharine M Bosio
Journal:  PLoS Pathog       Date:  2010-05-27       Impact factor: 6.823

8.  B1a cells enhance susceptibility to infection with virulent Francisella tularensis via modulation of NK/NKT cell responses.

Authors:  Deborah D Crane; Amanda J Griffin; Tara D Wehrly; Catharine M Bosio
Journal:  J Immunol       Date:  2013-02-01       Impact factor: 5.422

9.  Francisella tularensis SchuS4 and SchuS4 lipids inhibit IL-12p40 in primary human dendritic cells by inhibition of IRF1 and IRF8.

Authors:  Robin Ireland; Rong Wang; Joshua B Alinger; Pamela Small; Catharine M Bosio
Journal:  J Immunol       Date:  2013-07-01       Impact factor: 5.422

10.  MiR-155 induction by F. novicida but not the virulent F. tularensis results in SHIP down-regulation and enhanced pro-inflammatory cytokine response.

Authors:  Thomas J Cremer; David H Ravneberg; Corey D Clay; Melissa G Piper-Hunter; Clay B Marsh; Terry S Elton; John S Gunn; Amal Amer; Thirumala-Devi Kanneganti; Larry S Schlesinger; Jonathan P Butchar; Susheela Tridandapani
Journal:  PLoS One       Date:  2009-12-30       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.